Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

Acquisitions - Narrative (Details)						3 Months Ended		9 Months Ended		39 Months Ended
Acquisitions - Narrative (Details)	Sep. 30, 2019 USD ($) $ / shares	Sep. 25, 2018 shares	Sep. 24, 2018 USD ($) therapy milestone $ / shares shares	Feb. 16, 2018 USD ($)	Nov. 17, 2017 USD ($) shares	Sep. 30, 2019 USD ($) $ / shares	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) $ / shares	Sep. 30, 2018 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2019 USD ($)	Jun. 29, 2019 USD ($)	Dec. 31, 2018 USD ($) $ / shares	Jun. 30, 2018 USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share) \| $ / shares	$ 0.001		$ 0.001			$ 0.001		$ 0.001					$ 0.001
Fair value of shares issued							$ 19,971,554		$ 19,971,554
Fair value of debt assumed	$ 0					$ 0	(15,075,000)	$ 0	(15,075,000)
Goodwill	16,411,123					16,411,123		16,411,123					$ 16,411,123
Impairment of intangible assets						0	159,687	1,449,121	$ 1,861,562
Inventory, net	402,267					402,267		402,267					1,110,780
Impairment of intangible assets							$ 1,900,000
Avadel
Business Acquisition [Line Items]
Cash				$ 1
Fair value of debt assumed				(15,075,000)
Contingent consideration				7,900,000
Goodwill				$ 3,778,001
Goodwill tax deductible period				15 years
Fair value assigned to intangible asset at purchase				$ 18,291,000
TRx
Business Acquisition [Line Items]
Cash					$ 18,900,000
Contingent consideration	0					$ 0		0					$ 0
Goodwill					12,633,122
Fair value assigned to intangible asset at purchase					$ 19,596,000
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) \| shares					7,534,884
Shares issued for purchase of business (in shares)					$ 8,514,419
Shares issued upon closing (in shares) \| shares					5,184,920
Contingent shares issuable as part of acquisition (in shares) \| shares					2,349,968
Goodwill, expected tax deductible amount					$ 8,700,000
PAI Sales & Marketing Agreement \| TRx
Business Acquisition [Line Items]
Fair value assigned to intangible asset at purchase					2,553,000
Flexichamber
Business Acquisition [Line Items]
Inventory, net											$ 0
Change in inventory reserve								200,000
Flexichamber \| Developed Technology Rights \| Avadel
Business Acquisition [Line Items]
Fair value assigned to intangible asset at purchase				$ 1,677,000							$ 0	$ 1,400,000
Impairment of intangible assets								$ 1,400,000
Nonrecurring \| Level 3 \| PAI Sales & Marketing Agreement \| TRx
Business Acquisition [Line Items]
Fair value of sales and marketing agreement														$ 0
Ichorion
Business Acquisition [Line Items]
Consideration issued (in shares) \| shares		5,800,000	5,800,000
Contingent consideration			$ 15,000,000
Fair value of shares issued			20,000,000
Intangible assets			18,700,000
Cash acquired			$ 1,600,000
Number of preclinical therapies \| therapy			3
Transaction costs			$ 200,000
Number of contingent consideration milestones \| milestone			3
Milestone payment	$ 0
Ichorion \| Assembled Workforce
Business Acquisition [Line Items]
Intangible assets			$ 200,000
Useful life			2 years
Milestone Two \| TRx
Business Acquisition [Line Items]
Contingent consideration					2,000,000
Milestone Three \| TRx
Business Acquisition [Line Items]
Contingent consideration					$ 2,000,000
Forecast \| Milestone One \| Ichorion
Business Acquisition [Line Items]
Milestone payment										$ 6,000,000
Forecast \| Milestone Two \| Ichorion
Business Acquisition [Line Items]
Milestone payment										5,000,000
Forecast \| Milestone Three \| Ichorion
Business Acquisition [Line Items]
Milestone payment										$ 4,000,000